MMP9 and diabetes mellitus: Emerging human data also suggest that GLP-1 receptor agonists may improve endothelial function while lowering MMP-9 in select metabolic settings (e.g., polycystic ovary syndrome), though current reports are small and disease-specific, underscoring the need for targeted trials in diabetes and cardiovascular cohorts [94].